MFG
IBRX icon

Merit Financial Group’s ImmunityBio IBRX Stock Holding History

Merit Financial Group’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$420K Buy
47,916
+3,351
+8% +$25.4K ﹤0.01% 1603
2026
Q1 		$342K Buy
44,565
+257
+0.6% +$1.76K ﹤0.01% 1583
2025
Q4 		$87.7K Sell
44,308
-710
-2% -$1.61K ﹤0.01% 1903
2025
Q3 		$111K Sell
45,018
-4,157
-8% -$10.7K ﹤0.01% 1730
2025
Q2 		$130K Buy
49,175
+4,931
+11% +$13.3K ﹤0.01% 1613
2025
Q1 		$133K Buy
44,244
+435
+1% +$1.32K ﹤0.01% 1341
2024
Q4 		$112K Buy
43,809
+9
+0% +$37 ﹤0.01% 1126
2024
Q3 		$163K Sell
43,800
-19
-0% -$88 ﹤0.01% 799
2024
Q2 		$277K Buy
43,819
+7
+0% +$46 0.01% 753
2024
Q1 		$401K Buy
43,812
+12
+0% +$54 0.01% 611
2023
Q4 		$220K Hold
43,800
– – 0.01% 701
2023
Q3 		$74K Buy
43,800
+20,000
+84% +$40.2K ﹤0.01% 727
2023
Q2 		$66.2K Hold
23,800
– – ﹤0.01% 728
2023
Q1 		$43.3K Buy
+23,800
New +$74K ﹤0.01% 616

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Merit Financial Group's IBRX Position: Q2 2026 in Review

Merit Financial Group increased its ImmunityBio (IBRX) stake by 7.5% in Q2 2026, buying an estimated $25.4K and bringing the position to 47,916 shares worth $420K. The position accounts for ﹤0.01% of the portfolio, ranked #1603.

Merit Financial Group first reported a position in IBRX in Q1 2023 and has held it in 14 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Merit Financial Group held 47,916 shares of ImmunityBio worth $420K as of Q2 2026.
  • Merit Financial Group bought 3,351 ImmunityBio shares in Q2 2026, an estimated $25.4K.
  • ImmunityBio made up ﹤0.01% of Merit Financial Group's portfolio in Q2 2026, its #1603 holding.
  • Merit Financial Group first reported a position in ImmunityBio in Q1 2023 and has held it in 14 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.